AstraZeneca's US trial could remain on hold
|AstraZeneca's US trial could remain on hold through midweek, and possibly longer, pending a US probe, Reuters reports.
- The trial in the US remains on hold as US regulators probe serious UK side effect.
Market implications
Markets have recovered fro the knee-jerk risk-off reaction last week.
Meanwhile, the UK trial of a leading coronavirus vaccine, which was abruptly halted last week because of safety concerns, restarted on Saturday after the university conducting the trial said an independent committee found that it was safe to do so.
The University of Oxford and pharmaceutical company AstraZeneca paused enrolment in the global trials of their vaccine candidate on 6 September, after a person participating in the UK trial experienced an adverse reaction.
Scientists say that a pause is not uncommon in large trials, and that a speedy resumption of testing was expected.
The episode shows that care is being taken with the trial, they say.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.